RxDoctor Payments Data

Anna Truitt

Primary Care · Ponchatoula, LANPI 1861196321

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,363, 5.6 times the $242 reported in 2023.

$2,515in general payments, 2019–2025

Across 140 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$593
  • Novo Nordisk$296
  • Pfizer$258
  • Lilly USA, LLC$225
  • AstraZeneca$221
  • Bayer$156
  • plus $766 from 16 others

What the payments were for

  • Food & beverage$2,515100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,515 in reported general payments places this provider in the 80th percentile of 106 primary care providers in Louisiana.

See all primary care providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$35,360
LinzessLinaclotide13$7,025
Pantoprazole Sodium38$563
Rosuvastatin Calcium32$555
Atorvastatin Calcium68$525
Levothyroxine Sodium59$422
Gabapentin22$402
Amlodipine Besylate83$396
FenofibrateFenofibrate Nanocrystallized14$360
Duloxetine Hcl15$306
Ezetimibe18$293
Losartan Potassium19$271
Metformin Hcl ErMetformin Hcl25$240
Albuterol Sulfate HfaAlbuterol Sulfate14$237
Pravastatin Sodium23$230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$296$35,36037 claims
AbbVieLinzess$593$7,02513 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$42259 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 primary care providers in Louisiana.

Other primary care in Ponchatoula

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →